Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Appoints Aqeel A. Fatmi, Ph.D. to Its Board of Directors
August 07, 2018 07:00 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) announced today the appointment of Aqeel A. Fatmi, Ph.D. to its Board of...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss Year-end Financial Results on June 15, 2018
June 11, 2018 07:00 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 11, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals and SunGen Pharma File ANDA for Extended-Release CNS Stimulant
May 30, 2018 07:30 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 30, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Announces Strategic Marketing Alliance with Glenmark Pharmaceuticals, Inc., USA NORTHVALE, N.J., May 29, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc (OTCBB:ELTP) announced today the signing of a license, manufacturing, and supply agreement with Glenmark Pharmaceuticals,...
visiongain Logo 72dpi.jpg
Visiongain Launches New Report on the Generic Drugs Market 2018-2028
May 21, 2018 07:34 ET | Visiongain Ltd
LONDON, May 21, 2018 (GLOBE NEWSWIRE) -- Visiongain has launched a new pharma report Generic Drugs Market Forecast 2018-2028: Growth in Leading Regional and National Markets – North America, Europe,...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Reports Positive Topline Results from SequestOx™ Pilot Study
January 30, 2018 08:35 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported positive topline results from a pilot study conducted for...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Reports Positive Topline Results from Pivotal Bioequivalence Studies for an Extended-Release Generic
January 10, 2018 08:00 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported positive topline results from pivotal bioequivalence studies for...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Announces FDA Approval of Phendimetrazine Tartrate Tablets USP
January 02, 2018 12:56 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2018 Ended September 30, 2017
November 09, 2017 16:59 ET | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
Groundbreaking prescription tool helps Canadians compare clinical and cost-effectiveness of drugs
November 08, 2017 09:43 ET | Reformulary Group
TORONTO, ON--(Marketwired - November 08, 2017) - Today, Reformulary Group, Canada's leading, independent drug plan management company, launched DrugFinder™, a consumer app that allows Canadians to...